tion of histone deacetylase 6 (HDAC6) inhibitor tubastatin A together with cyclooxygenase-2 (COX-2) inhibitor celecoxib resulted in synergistic antitumor effects in CAL 27 and SACC-83 cells. Treatment with celecoxib alone promoted the membrane translocation of phosphatase and tensin homolog (PTEN),
GUANHUA ZHANG,YE-HUA GAN
2017-01-01
Abstract:Chemotherapy is one of the most effective nonsurgical treatments for various types of tumor. Identifying different combinations of antitumor agents that can produce synergistic antitumor effects remains an important clinical strategy. In the present study, we showed that the combination of histone deacetylase 6 (HDAC6) inhibitor tubastatin A together with cyclooxygenase-2 (COX-2) inhibitor celecoxib resulted in synergistic antitumor effects in CAL 27 and SACC-83 cells. Treatment with celecoxib alone promoted the membrane translocation of phosphatase and tensin homolog (PTEN), indicating PTEN activation, and consequently led to protein kinase B (AKT) dephosphorylation (inactivation). Similarly, treatment with an HDAC6 inhibitor alone promoted PTEN membrane translocation and correspondingly dephosphorylated AKT. The combination of celecoxib and an HDAC6 inhibitor synergistically increased PTEN membrane translocation and inactivated AKT. Moreover, celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects in PTEN-deficient U-87 MG cells that had been stably transfected with wild-type PTEN, but not in the same cell line stably transfected with mutant PTEN-K163R, which cannot be activated by HDAC6 inhibitors. In summary, the results indicated that the COX-2 inhibitor celecoxib enhanced the HDAC6 inhibitor-induced antitumor effects by activating the PTEN/AKT signaling pathway. Introduction Chemotherapy is one of the major strategies for cancer treatment, and functions by targeting the physiological characteristics of cancer cells, including proliferation, angiogenesis, apoptosis, invasion and migration (1). However, drug resistance (2) and severe side-effects (3) still hinder the effects of chemotherapy. The use of drug combinations has numerous benefits for cancer therapy. It enhances the therapeutic effects or decreases the required dosages of each drug thereby reducing the severity of adverse effects (4). Thus, the search for combinations of agents that can achieve synergistic antitumor effects remains an important strategy with which to improve the effects of chemotherapy. Acetylation is a major form of protein post-translational modification and is responsible for regulating various cellular processes, including cell proliferation and cell survival (5). Acetylation is catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs transfer acetyl groups to lysine residues, whereas HDACs remove acetyl groups from lysine residues (6). In total, 18 human HDACs have been identified, which are categorized into four classes: Class I (HDAC1, HDAC2, HDAC3 and HDAC8), IIa (HDAC4, HDAC5, HDAC7 and HDAC9), IIb (HDAC6 and 10) and IV (HDAC11) are classical HDACs, whose activities are inhibited by pan-HDAC inhibitors, such as trichostatin A; whereas class III HDACs, also known as sirtuins, are not affected by trichostatin A (7). HDACs are overexpressed in many types of tumors, and inhibition of HDACs can result in the inhibition of cell proliferation and induction of apoptosis (8). HDAC inhibitors can achieve antitumor effects through the phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) signaling pathway (9,10). To date, three pan-HDAC inhibitors, namely vorinostat (SAHA), belinostat (PXD-101) and panobinostat (LBH-589), have been approved by the US Food and Drug Administration (FDA) for the treatment of cancer (11). Clinical application of pan-HDAC inhibitors can result in several adverse side-effects, such as fatigue, diarrhea, bone marrow toxicity and thrombocytopenia (12). This is likely due to the fact that most HDACs are necessary for important biological processes; knockout of HDAC1, or most other Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN GUANHUA ZHANG1,2 and YE-HUA GAN1,2 1Central Laboratory and 2Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Haidian, Beijing 100081, P.R. China Received March 15, 2017; Accepted August 11, 2017 DOI: 10.3892/or.2017.5981 Correspondence to: Dr Ye-Hua Gan, Central Laboratory, Peking University School of Stomatology, 22 Zhongguancun Avenue South, Haidian, Beijing 100081, P.R. China E-mail: kqyehuagan@bjmu.edu.cn